Acerus Pharmaceuticals reported its financial results for the three and twelve-month period ended December 31, 2019.
Acerus Pharmaceuticals (TSX:ASP) reported its financial results for the three and twelve-month period ended December 31, 2019.
As quoted in the press release:
Amended and restated (“A&R”) partnership agreement with Aytu Bioscience (“Aytu”) becomes fully functional which should allow for accelerated growth of NATESTO® in the United States
Multiple scientific publications and congress presentations highlighting the unique clinical profile of NATESTO®
Avanafil New Drug Submission filed with Health Canada
Multiple financing transactions in 2019 and 2020 raising over $30 million to fund future growth